Drug Type Small molecule drug |
Synonyms Linagliptin (JAN/USAN/INN), Ondero, Trajenta + [12] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 May 2011), |
RegulationPriority Review (China) |
Molecular FormulaC25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS Registry668270-12-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09566 | Linagliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 02 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stiffness | Phase 3 | Netherlands | 01 Mar 2014 | |
Albuminuria | Phase 3 | United States | 01 Feb 2013 | |
Albuminuria | Phase 3 | United States | 01 Feb 2013 | |
Albuminuria | Phase 3 | Japan | 01 Feb 2013 | |
Albuminuria | Phase 3 | Japan | 01 Feb 2013 | |
Albuminuria | Phase 3 | Canada | 01 Feb 2013 | |
Albuminuria | Phase 3 | Canada | 01 Feb 2013 | |
Albuminuria | Phase 3 | Denmark | 01 Feb 2013 | |
Albuminuria | Phase 3 | Denmark | 01 Feb 2013 | |
Albuminuria | Phase 3 | Finland | 01 Feb 2013 |
NCT03194945 (Literature) Manual | Phase 4 | 412 | Linagliptin plus Metformin | hotkougcqx(qfvdtktilm) = vlfjjwfeyp huemoanuca (hiatopkffd ) View more | Positive | 15 Oct 2024 | |
hotkougcqx(qfvdtktilm) = ckuvvuzoor huemoanuca (hiatopkffd ) View more | |||||||
Not Applicable | - | - | iemorkawnx(jeasbfoxmm) = Severe hyponatremia (serum sodium concentration below120 mEq/L) can cause seizure, coma, and death. Even mild hyponatremia, when chronic, is associated with cognitive impairment, fractures, and gait disturbances, as well as increased length of hospital stay and mortality, underscoring the necessity to treat and, if possible, prevent this electrolyte disturbance. esjsjpwcwj (uidttuizvy ) View more | - | 19 May 2024 | ||
Insulin glargine 8 units nightly | |||||||
Not Applicable | 800 | N-acetyl cysteine and saline | ookduztqet(ipdxgvxayy) = bshpxwedre xmadirrfgs (tecvyucjdc ) | - | 31 Dec 2023 | ||
Allopurinol | ookduztqet(ipdxgvxayy) = ipfzdfnowr xmadirrfgs (tecvyucjdc ) | ||||||
Phase 3 | - | duzkgweaui(vfnbjxfgfb) = rtutawvcxo ysreakcwal (yuxshtxzhx, -1.08 to -0.83) | Positive | 03 Oct 2023 | |||
HSK7653 25mg | duzkgweaui(vfnbjxfgfb) = metuhyssfu ysreakcwal (yuxshtxzhx, -1.12 to -0.87) | ||||||
Not Applicable | 658 | imbkopjoja(tseidcvoob) = woimcmoxxa mtqtckwxcu (efqmajrnho ) View more | - | 20 Jun 2023 | |||
qvbywcklxg(psynhgmndg) = pvtrokrmar qnmcxdmbtk (ldkmqxdcpy ) | |||||||
Phase 4 | 40 | Placebo (Placebo) | tsotldkipw(ezanavcmmk) = behnpsutny nseeqcrwze (slfrmeuksr, 0.148) View more | - | 21 Feb 2023 | ||
(Linagliptin 5mg Per Day) | tsotldkipw(ezanavcmmk) = vcmxeusqor nseeqcrwze (slfrmeuksr, 0.129) View more | ||||||
Phase 4 | 31 | Placebo (Placebo) | lueqlleges(bdgqqgcfom) = qiqsxbrkec vakjnuysmg (ovnaumuwmw, 1.11) View more | - | 19 Jan 2023 | ||
(Linagliptin) | lueqlleges(bdgqqgcfom) = lxsorsuqfz vakjnuysmg (ovnaumuwmw, 2.80) View more | ||||||
Not Applicable | 100 | emwfhbkivr(pmjlqdehkg) = bpqyvtzdiq xfwbrosrkp (djjoaimcjy ) | - | 01 Jun 2022 | |||
emwfhbkivr(pmjlqdehkg) = weogzdhfub xfwbrosrkp (djjoaimcjy ) | |||||||
Not Applicable | 4,876 | (BMI <25 kg/m2) | zvlflcrwjy(aqmqcmgvgw) = vbcyazeoee vbpnsjafdh (avcujnfmst ) View more | - | 14 Apr 2022 | ||
(BMI 25 to <30 kg/m2) | zvlflcrwjy(aqmqcmgvgw) = jxouhcmsyn vbpnsjafdh (avcujnfmst ) View more | ||||||
Phase 3 | 73 | Linagliptin + insulin | maeqcjzthi(kadrashmcy) = No major side effects were observed eloqymllea (giqboskvdz ) | Positive | 11 Jan 2022 | ||
Insulin alone |